NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1NBIX • US64125C1099
1NBIX.MI Key Statistics, Chart & Performance
The current stock price of 1NBIX.MI is 131.55 EUR.
1NBIX.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1NBIX.MI.
1NBIX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI. Both the health and profitability get an excellent rating, making 1NBIX.MI a very profitable company, without any liquidiy or solvency issues.
1NBIX.MI Financial Highlights
Over the last trailing twelve months 1NBIX.MI reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS increased by 12.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.95% | ||
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| Debt/Equity | 0 |
1NBIX.MI Forecast & Estimates
35 analysts have analysed 1NBIX.MI and the average price target is 155.07 EUR. This implies a price increase of 17.88% is expected in the next year compared to the current price of 131.55.
For the next year, analysts expect an EPS growth of 55.94% and a revenue growth 21.48% for 1NBIX.MI
1NBIX.MI Ownership
1NBIX.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.41 | 44.346B | ||
| ARGX | ARGENX SE | 27.37 | 44.309B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.797B | ||
| ABVX | ABIVAX SA | N/A | 7.491B | ||
| 2X1 | ABIVAX SA | N/A | 7.46B | ||
| GLPG | GALAPAGOS NV | N/A | 1.885B | ||
| GXE | GALAPAGOS NV | N/A | 1.885B | ||
| IVA | INVENTIVA SA | N/A | 978.821M | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| NANO | NANOBIOTIX | N/A | 877.756M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1NBIX.MI
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA US
Employees: 1800
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ
Can you describe the business of NEUROCRINE BIOSCIENCES INC?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the current price of 1NBIX stock?
The current stock price of 1NBIX.MI is 131.55 EUR. The price increased by 4.9% in the last trading session.
Does NEUROCRINE BIOSCIENCES INC pay dividends?
1NBIX.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1NBIX stock?
1NBIX.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for 1NBIX.MI stock?
35 analysts have analysed 1NBIX.MI and the average price target is 155.07 EUR. This implies a price increase of 17.88% is expected in the next year compared to the current price of 131.55.
What is the GICS sector and industry of 1NBIX stock?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) operates in the Health Care sector and the Biotechnology industry.
Would investing in NEUROCRINE BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1NBIX.MI.